Tags

Type your tag names separated by a space and hit enter

Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor V beta 8.2 segment.
Eur J Immunol. 1995 Jul; 25(7):1960-4.EJ

Abstract

The predominance of T cell receptor (TCR) V beta 8.2 utilization by encephalitogenic T cells induced in Lewis rats by immunization with myelin basic protein (MBP) is controversial. Thus, both an almost exclusive usage of V beta 8.2 [Burns, F. R., Li, X., Shen, N., Offner, H., Chou, Y. K., Vandenbark, A. A. and Heber-Katz, E., J. Exp. Med. 1989, 169: 27; Chluba, J., Steeg, C., Becker, A., Wekerle, H. and Epplen, J. T., Eur. J. Immunol. 1989. 19: 279] and a quite diverse V beta composition of CD4 T cells causing experimental autoimmune encephalomyelitis (EAE) [Sun, D., Gold, P. D., Smith, L., Brostoff, S. and Coleclough, C., Eur. J. Immunol, 1992. 22: 591; Sun, D., Le, J. and Coleclough, C., Eur. J. Immunol. 1993. 23: 494] have been reported. Using a recently developed monoclonal antibody (mAb) specific for TCR V beta 8.2, we show that postnatal treatment effectively eliminates V beta 8.2-bearing cells and prevents MBP-induced EAE in the majority of Lewis rats. Moreover, treatment of adult Lewis rats with V beta 8.2-specific mAb as late as on day 12 after MBP immunization suppressed the development of neurological symptoms. Thus, V beta 8.2-bearing cells do play a decisive role in Lewis rat EAE, and suppression of the small (5%) V beta 8.2-expressing T cell subset provides an effective therapeutic strategy.

Authors+Show Affiliations

Institute for Virology and Immunobiology, University of Würzburg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7542597

Citation

Imrich, H, et al. "Prevention and Treatment of Lewis Rat Experimental Allergic Encephalomyelitis With a Monoclonal Antibody to the T Cell Receptor V Beta 8.2 Segment." European Journal of Immunology, vol. 25, no. 7, 1995, pp. 1960-4.
Imrich H, Kugler C, Torres-Nagel N, et al. Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor V beta 8.2 segment. Eur J Immunol. 1995;25(7):1960-4.
Imrich, H., Kugler, C., Torres-Nagel, N., Dörries, R., & Hünig, T. (1995). Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor V beta 8.2 segment. European Journal of Immunology, 25(7), 1960-4.
Imrich H, et al. Prevention and Treatment of Lewis Rat Experimental Allergic Encephalomyelitis With a Monoclonal Antibody to the T Cell Receptor V Beta 8.2 Segment. Eur J Immunol. 1995;25(7):1960-4. PubMed PMID: 7542597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor V beta 8.2 segment. AU - Imrich,H, AU - Kugler,C, AU - Torres-Nagel,N, AU - Dörries,R, AU - Hünig,T, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 1960 EP - 4 JF - European journal of immunology JO - Eur J Immunol VL - 25 IS - 7 N2 - The predominance of T cell receptor (TCR) V beta 8.2 utilization by encephalitogenic T cells induced in Lewis rats by immunization with myelin basic protein (MBP) is controversial. Thus, both an almost exclusive usage of V beta 8.2 [Burns, F. R., Li, X., Shen, N., Offner, H., Chou, Y. K., Vandenbark, A. A. and Heber-Katz, E., J. Exp. Med. 1989, 169: 27; Chluba, J., Steeg, C., Becker, A., Wekerle, H. and Epplen, J. T., Eur. J. Immunol. 1989. 19: 279] and a quite diverse V beta composition of CD4 T cells causing experimental autoimmune encephalomyelitis (EAE) [Sun, D., Gold, P. D., Smith, L., Brostoff, S. and Coleclough, C., Eur. J. Immunol, 1992. 22: 591; Sun, D., Le, J. and Coleclough, C., Eur. J. Immunol. 1993. 23: 494] have been reported. Using a recently developed monoclonal antibody (mAb) specific for TCR V beta 8.2, we show that postnatal treatment effectively eliminates V beta 8.2-bearing cells and prevents MBP-induced EAE in the majority of Lewis rats. Moreover, treatment of adult Lewis rats with V beta 8.2-specific mAb as late as on day 12 after MBP immunization suppressed the development of neurological symptoms. Thus, V beta 8.2-bearing cells do play a decisive role in Lewis rat EAE, and suppression of the small (5%) V beta 8.2-expressing T cell subset provides an effective therapeutic strategy. SN - 0014-2980 UR - https://www.unboundmedicine.com/medline/citation/7542597/Prevention_and_treatment_of_Lewis_rat_experimental_allergic_encephalomyelitis_with_a_monoclonal_antibody_to_the_T_cell_receptor_V_beta_8_2_segment_ L2 - https://doi.org/10.1002/eji.1830250724 DB - PRIME DP - Unbound Medicine ER -